← Leaderboards
Steven Hsesheng Lin
Creatv Microtech, Inc.
$6,260,289
Attributed
$8,159,625
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,519,099 · 9
By mechanism
P01$2,866,447 · 2
U01$2,862,955 · 1
U54$1,714,312 · 3
R21$770,385 · 2
R43$305,000 · 1
Top collaborators
- Sunil Krishnan5 shared
- Boyi Gan3 shared
- Daniel L. Adams2 shared
- Gheath Al-Atrash2 shared
- Spencer Rae Rosario2 shared
- Yi Lu1 shared
- Cha-Mei Tang1 shared
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorMalignant NeoplasmsCellsRadiation TherapyFutureImmunePre-Clinical ModelCancer TypeTreatment OutcomeMalignant Neoplasm Of LungChemoradiationCancer TherapyRadiationResistanceClinical TranslationMalignant Neoplasm Of EsophagusHeterogeneityImageResponseLinkBaseImmunotherapySolid NeoplasmCancer Cell
Grant awards (24)
Project 2: Radiation-Induced Lymphopenia: Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies.$558,368
P01 · FY2025 · CA · contact PI
Role of genomic and microenvironment factors in conferring acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma$278,298
U54 · FY2025 · CA · contact PI
Project 2: Radiation-Induced Lymphopenia: Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies.$530,451
P01 · FY2024 · CA · contact PI
Role of genomic and microenvironment factors in conferring acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma$263,522
U54 · FY2024 · CA · contact PI
Administrative Supplement: Investigating the role of iron redox dynamics in radiation resistance in esophageal cancer$177,125
U54 · FY2024 · CA
Project 2: Radiation-Induced Lymphopenia: Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies.$578,510
P01 · FY2023 · CA · contact PI
Role of genomic and microenvironment factors in conferring acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma$284,543
U54 · FY2023 · CA · contact PI
Admin-Core-001$182,349
U54 · FY2023 · CA
Administrative Supplement: Metabolic Alterations Associated with Acquired Resistance to Ferroptosis in Esophageal Cancer$182,349
U54 · FY2023 · CA
Project 2: Radiation-Induced Lymphopenia: Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies.$552,100
P01 · FY2022 · CA · contact PI
Role of genomic and microenvironment factors in conferring acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma$346,126
U54 · FY2022 · CA · contact PI
Project 2: Radiation-Induced Lymphopenia: Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies.$647,018
P01 · FY2021 · CA · contact PI
Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches$596,334
U01 · FY2021 · CA · contact PI
Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte Infusion$176,175
R21 · FY2021 · CA · contact PI
Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches$495,509
U01 · FY2020 · CA · contact PI
Targeting Tankyrases to Mitigate Immunosuppression and Enhance Cancer Immunotherapy$174,000
R21 · FY2020 · CA · contact PI
Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches$578,444
U01 · FY2019 · CA · contact PI
Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte Infusion$211,410
R21 · FY2019 · CA · contact PI
Targeting Tankyrases to Mitigate Immunosuppression and Enhance Cancer Immunotherapy$208,800
R21 · FY2019 · CA · contact PI
I-Corps for SBIR Phase I: Giant Macrophage-like Cells as a blood-based Biomarker for Lung Cancer Recurrence$55,000
R43 · FY2019 · CA
Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches$596,334
U01 · FY2018 · CA · contact PI
Giant Macrophage-like Cells as a blood-based Biomarker for Lung Cancer Recurrence$67,150
R43 · FY2018 · CA
Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches$596,334
U01 · FY2017 · CA · contact PI
Giant Macrophage-like Cells as a blood-based Biomarker for Lung Cancer Recurrence$182,850
R43 · FY2017 · CA